12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
In Rural Mut. Ins. Co. v. Lester Bldgs., LLC 2019 WI 70, 2019 Wisc. LEXIS 272, the Supreme Court of ...
Read More >
Colorado has become the latest jurisdiction to join the “ban the box” movement. The Colorado Chanc...
Read More >
Beginning as early as June 30, 2020, California employers with 5 or more California-based employees ...
Read More >
Last week, the Antitrust Division (Division) of the U.S. Department of Justice (Department or DOJ) i...
Read More >
The National Labor Relations Act (NLRA) grants employees “the right to self-organization, to form, ...
Read More >
Today our employer focused legislative update zeroes in on “no rehire” provisions in settlement ag...
Read More >